Illustrative image – not actual.Vivimed Labs has mopped up funds through allotment of shares to private equity (PE) companies.
The company has raised Rs 127 crore through preferential allotment of shares to NYLIM Jacob Ballas India Fund and Kitara Capital. The JB Fund has invested Rs 67 crore to subscribe for compulsorily convertible preference shares which will be converted within 18 months. This will account for a 13.2 per cent stake in the Vivimed on a fully diluted basis. Kitara Capital has invested Rs 60 crore to subscribe for equity shares at Rs 327 a share, for a 11.4 per cent stake.
The proceeds will be utilised to finance Vivimed's ongoing expansion plans for speciality chemicals at its existing locations in Bidar (Karnataka), Hyderabad and Visakhapatnam (Andhra Pradesh). Also, a part of funds will be used in setting up of a greenfield project at Pydibhimavaram near Visakhapatnam and a plant at Choutuppal in Andhra Pradesh.
